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Early events during primary HIV infection (PHI) are thought to influence disease outcome. 
Although a growing body of evidence suggests a beneficial role of HIV-specific CD4 help 
in HIV infection, it is unclear how early viral replication, systemic immune activation, and 
antiretroviral therapy (ART) may shape CD4 T-cell responses during PHI, and whether 
HIV-specific CD4 responses contribute to the high immune activation observed in PHI. 
Twenty-seven patients with early PHI were included in a prospective longitudinal study 
and 12 of them received ART after enrollment. Fresh peripheral blood mononuclear 
cells were used for measurement of ex vivo T-cell activation and of cytokine-produc-
ing CD4 T-cells following stimulation with PMA/ionomycin or HIV-1-gag-p24 antigen. 
Patients were segregated based on CD8 T-cell activation level (i.e., % HLA-DR+CD38+ 
CD8 T-cells) at baseline (BL). Patients with lower immune activation exhibited higher 
frequency of bulk CD4 T-cells producing IFN-γ or IL-17 and higher effector-to-regulatory 
cell ratios. No differences were found in HIV-specific CD4 T-cell frequencies. In contrast, 
segregation of patients based on plasma viral load (pVL) revealed that patients with 
higher pVL showed higher cytokine-producing HIV-specific CD4 responses. Of note, the 
frequency of IFN-γ+ HIV-specific CD4 T cells significantly diminished between BL and 
month 6 only in ART-treated patients. However, early treatment initiation was associated 
with better maintenance of HIV-specific IFN-γ+ CD4 T-cells. These data suggest that 
HIV-specific CD4 responses do not fuel systemic T-cell activation and are driven by 
viral replication but not able to contribute to its control in the early phase of infection. 
Moreover, our data also suggest a benefit of early treatment for the maintenance of 
HIV-specific CD4 T-cell help.
Keywords: hiV-specific cD4 T cells, acute hiV infection, viral load, generalized immune activation, antiretroviral 
therapy, early arT initiation
inTrODUcTiOn
CD4 T helper cells are crucial to orchestrate immune responses to viral infections by recruiting 
key immune cells into tissues, by providing help for expansion and function of B cells and CD8 
T cells, and by direct cell-mediated cytotoxicity (1). While extensive research deciphered the ability 
of CD8 T cells to control HIV viral replication, CD4 T cells have long been neglected as effectors in 
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HIV immunity owing to the fact that they are the major targets 
of the virus (2). Nevertheless, several studies ascribed a protec-
tive role to HIV-specific CD4 T cells with regard to viremia and 
disease progression (3–7), as well as in vaccine-mediated protec-
tion against HIV acquisition (8, 9). T helper responses during 
primary HIV infection (PHI) may be of particular interest as 
early events are thought to influence disease outcome. Although 
HIV-specific proliferative CD4 T-cell responses are quite limited 
in most patients during PHI (10), cytokine-producing virus-
specific CD4 T cells have been clearly identified during PHI in 
several recent studies (4, 11–13). Of note, HIV-specific CD4 and 
CD8 T cells arise with distinct kinetics during PHI, with specific 
CD4 T cells reaching their maximal frequency within few weeks 
post-infection, while CD8 T cells gradually increase for several 
months (11).
Although it was first considered “unlikely” that early estab-
lished CD4 T cell responses were related to the control of viremia 
(13), three recent studies clearly reported a beneficial role for 
HIV-specific CD4 T cells in PHI with regard to viral set point 
(4) and clinical progression (6, 12), in line with interventional 
experiments conducted in acute SIV infection (14).
Thus, a growing body of evidence supports a highly important 
role for HIV-specific CD4 T cells, which alleviates the fear that 
activation of these cells may fuel viral spreading and accelerate 
disease progression, as suggested (15). Conversely, it remains 
unclear how viral replication and systemic immune activation 
– both particularly high during PHI – may shape effector CD4 
T-cell responses, and whether HIV-specific CD4 responses con-
tribute to the immune activation in early infection. In this study, 
we thus investigated both polyclonal and HIV-specific cytokine-
producing CD4 T cells as a function of the immuno-virological 
status of patients diagnosed with early acute HIV infection. 
We describe here interrelationships between viral replication, 




Individuals with acute HIV infection were recruited in a mul-
ticenter prospective study. These patients have been described 
elsewhere (16–18). Acute HIV infection was defined by <3 
bands on HIV Western Blot, a positive p24 antigenaemia and/or 
a detectable plasma HIV-RNA with a negative or weakly positive 
ELISA. The estimated date of infection was calculated as 2 weeks 
before onset of symptoms for patients with symptomatic PHI 
or 4 weeks before the first positive Western Blot. At enrollment 
[baseline (BL)], all patients were treatment-naive. Some of the 
patients initiated antiretroviral treatment (ART) within 3 months, 
based on CD4 cell counts and the decision of both physicians 
and patients. Peripheral blood was collected in EDTA-containing 
tubes at BL and at month 6 of follow-up (M6). Written informed 
consent was provided by all patients, and the study was approved 
by the ethical committee of Ile de France II. Plasma HIV-RNA 
levels and CD4 counts were determined in the four recruiting 
hospitals, using the locally available technique with a maximum 
detection limit of 20 copies/mL.
Flow cytometric analysis
Fresh peripheral blood mononuclear cells (PBMCs) were puri-
fied by density gradient centrifugation (Isopaque-Ficoll) within 
2–4 h after blood sampling. Only freshly isolated cells were used 
in this study to avoid any bias due to cryopreservation. Cells were 
stained using multicolor panels and analyzed by flow-cytometry 
(LSRII cytometer, Becton Dickinson) as described previously 
(19). The following monoclonal antibodies (mAbs) conjugated 
to PE Texas Red (ECD), allophycocyanin (APC)–Hilite7 (H7), 
Alexa Fluor 488 (AF488), Alexa Fluor 700 (AF700), APC, 
peridinin chlorophyll protein–cyanin 5.5 (PerCP–Cy5.5), 
fluorescein isothiocyanate (FITC), Alexa Fluor 647 (AF647), and 
phycoerythrin–cyanin 7 (PE–Cy7) were used at predetermined 
optimal concentrations: anti-CD3–ECD (Beckman Coulter); 
anti-CD4–APC–H7, anti-CD8–AF488, anti-CD8–AF700, anti-
CD25–APC, anti-CD38–APC, anti-HLA-DR–PerCP–Cy5.5, 
anti-IFN-γ–AF700, anti-IL-2–FITC, anti-IL-17–AF647 (BD 
Biosciences); anti-CD127–PE–Cy7, anti-FoxP3–AF700 (eBio-
sciences); and anti-Ki-67–FITC (Dako).
FcR Blocking Reagent (Miltenyi Biotec) was used to block 
unwanted binding of antibodies and increase the staining speci-
ficity of cell surface antigens. For intracellular staining of IFN-γ, 
IL-2, IL-17, FoxP3, or Ki-67, cells were fixed and permeabilized 
using the “FoxP3 Staining Buffer Set” (eBioscience) according to 
the manufacturer’s recommendations. Analyses were performed 
using the FlowJo software (TreeStar).
Measurement of cD4 T-cell responses
CD4 T-cell isolation from fresh blood samples was performed 
prior to density gradient centrifugation by incubating the blood 
with the “RosetteSep human CD4 T-cell enrichment” antibody 
cocktail (Stem Cell Technologies) according to the manufacturer’s 
recommendations. For assessment of “polyclonal” responses, 
freshly isolated CD4 T cells were stimulated with PMA (5 ng/mL) 
and ionomycin (1 μg/mL) at 37°C for 5 h. After 2 h of culture, 
brefeldin A (5 μg/mL) (Sigma-Aldrich) was added. Measurement 
of HIV-specific CD4 T-cell responses was performed by stimulat-
ing the cells with recombinant HIV-1 gag p24 protein (5 μg/mL, 
provided by the Agence Nationale de la Recherche sur le Sida) in 
the presence of autologous monocytes (monocyte/CD4 T cell 
ratio of 1:10) for 3 days. Intracellular cytokine staining (ICS) was 
performed as described above.
statistical analysis
Non-parametric tests were used to avoid the impact of potential 
outlier values in a small study. Comparisons between groups 
of patients were performed using the Mann–Whitney test. The 
Wilcoxon matched pairs test was used to estimate the changes in 
the different variables throughout the follow-up (BL vs. month 6). 
P-values below 0.05 were considered statistically significant.
resUlTs
study Population
Twenty-seven patients with early untreated PHI were included 
in a prospective longitudinal study and followed up for 
6  months, as previously described (16, 18). Median (IQR) 
TaBle 1 | Patients’ characteristics.
Time  
points




Baseline Untreated 5.65 (4.57–6.25) 490 (337–615)
n = 27
Month 6 Untreated 4.40 (3.50–4.80) 669 (457–725)
n = 13
Month 6 ART-treated 1.30 (1.00–1.33) 750 (593–783)
n = 12
Data are expressed as median (IQR).
Two patients were lost to follow-up.
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of estimated time post-infection at BL was 42  days (29–50). 
Twelve patients received ART after enrollment. Patients’ clinical 
characteristics at BL and at month 6 (M6) of follow-up are 
shown in Table  1.
Patients with a higher cD8 T-cell 
activation level exhibit lower Polyclonal 
cD4 T-cell responses
Two groups of patients were segregated based on the level of 
CD8 T-cell activation at BL: (i) a group with a high immune 
activation (“HIA patients,” n = 14), i.e., % HLA-DR+CD38+ CD8 
T cells ≥ median (27.6%) and (ii) a group with a low immune 
activation (“LIA patients,” n  =  13), i.e., % HLA-DR+CD38+ 
among CD8 T cells <  median (Figure  1A). As expected, HIA 
patients had also a higher frequency of CD8 T cells expressing 
the activation/proliferation marker Ki-67 as compared with LIA 
patients (median 58.3% vs. 20.1%; p = 0.0006, data not shown). 
Also as expected, HIA patients had higher plasma HIV-RNA 
levels (p = 0.021, Figure 1B); in contrast, CD4 T-cell counts were 
similar in both groups (Figure 1C). There was only a trend to a 
higher proportion of HLA-DR-expressing CD4 T cells in HIA 
patients and no significant difference for Ki-67+ CD4 T cells 
(Figures 1D,E). The estimated time from infection did not differ 
between groups (data not shown).
Following 5 h PMA/ionomycin activation of freshly isolated 
CD4 T cells (Figure S1A in Supplementary Material), HIA 
patients exhibited a significantly lower frequency of IFN-γ+ and 
IL-17+ single positive CD4 T cells as compared to LIA patients 
(p =  0.039 and p =  0.018, respectively), while frequencies of 
IFN-γ+IL-17+ double positive cells were similar (Figures 1F–H). 
Although there was a trend to a lower frequency of IFN-
γ+IL-2+ double positive CD4 T cells in HIA patients (p = 0.09, 
Figure 1I), IL-2 expression did not differ between groups (data 
not shown).
Importantly, frequencies of HIV-specific CD4 T cells − as 
measured by IFN-γ, IL-2, or IL-17 expression following gag-p24 
stimulation – were similar in HIA and LIA patients (data not 
shown).
As natural regulatory T cells (Tregs) can dampen CD4 T-cell 
responses, it was of interest to assess the balance between 
effector CD4 T cells and Tregs. We thus measured the ex vivo 
frequency of Treg cells, defined as CD25+CD127lowFoxP3+ CD4 
T cells. Interestingly, HIA patients exhibited lower effector/
regulatory T-cell balance when considering the Th1/Treg ratio 
(Figure  1J) as well as the Th17/Treg ratio [data not shown 
and Ref. (16)].
Patients with a higher Plasma Viral 
load exhibit higher hiV-specific cD4 
T-cell responses
Two groups of patients were next segregated based on the level of 
plasma viral load at BL: (i) a group with a high viral load (“HVL 
patients,” n = 13), i.e., plasma HIV-RNA levels > median (5.65 log 
copies/mL) and (ii) a group with a low viral load (“LVL patients,” 
n =  14), i.e., plasma HIV-RNA levels ≤  median (Figure  2A). 
HVL patients exhibited higher CD8 T-cell activation (p = 0.024, 
Figure  2B) and showed lower peripheral CD4 T-cell counts 
(p =  0.0002, Figure 2C) as compared with LVL patients. HVL 
patients also exhibited higher CD4 T-cell activation (Figure 2D). 
Of note, although T-cell activation (% HLA-DR+CD38+ in 
CD8 T cells) and plasma viral load were strongly correlated in 
this cohort of patients [R = 0.66 and p = 0.0002 (16)], HIA and 
HVL groups were not identical as 5/14 (36%) patients from the 
HIA group belonged to the LVL group, suggesting that immune 
activation and viral load are correlated but independent variables 
(Fisher’s exact test: p = 0.12).
HIV-specific CD4 T-cell responses were measured following 
72  h stimulation with the HIV-1 gag p24 protein (Figure S1B 
in Supplementary Material). HVL patients showed signifi-
cantly  higher frequency of IFN-γ+, IL-2+, IL-17+, and IFN-
γ+IL-17+ HIV-specific CD4 T cells compared with LVL patients 
(Figures  2E–H). Moreover, we found a direct relationship 
between the frequency of IL-2-producing HIV-specific CD4 
T cells and both the plasma viral load (Figure 3A) and the size 
of blood HIV reservoirs as assessed by total cell-associated HIV-
DNA (Figure 3B).
Of note, following PMA/ionomycin stimulation, there was no 
difference in Th1 responses between both groups. There was a 
trend to a lower frequency of IL-17-expressing CD4 T-cells in 
HVL patients compared with LVL patients (data not shown).
effect of early arT initiation on  
hiV-specific cD4 T-cell responses
We next assessed HIV-specific responses at month 6 of follow-
up and compared untreated patients and ART-treated patients. 
At month 6, all treated patients had plasma HIV-RNA levels 
<400 copies/mL.
Interestingly, the frequency of IFN-γ+ − but not of IL-2+ − 
p24-specific CD4 T cells significantly decreased between BL and 
month 6 in ART-treated patients but not in untreated patients 
(Figures 4A,B). There was also a trend to a decrease in IL-17+ 
p24-specific CD4 T cells only in ART-treated patients (p = 0.08), 
which was significant when considering CCR6+IL-17+ cells 
(p = 0.019) (data not shown).
In addition, we evaluated the impact of the time interval 
between estimated date of infection and treatment initiation. 
Notably, the level of IFN-γ+ p24-specific CD4 T cells at month 
6 negatively correlated with the time to treatment (Figure 4C). 
Thus, although the ART-mediated control of viral burden 
reduced the level of HIV-specific CD4 T cell IFN-γ responses, 
FigUre 2 | Patients with higher plasma viral load show higher hiV-specific cD4 T-cell responses in early Phi. Patients were segregated based on the 
level of plasma viral load at baseline: the group with higher viral load (HVL) was defined as blood HIV-RNA copies/mL > median and the group with lower viral 
load (LVL) as HIV-RNA copies/mL ≤ median (a). CD8 T-cell activation levels (% HLA-DR+CD38+ CD8 T cells) (B), CD4 T-cell counts (c), and % HLA-DR+ CD4 
T cells (D) are depicted in both patient groups. Freshly isolated CD4 T cells (at baseline) were stimulated with HIV-1 gag p24 protein for 72 h and frequencies of 
IFN-γ+ (e), IL-17+ (F), IL-2+ (g), as well as of IFN-γ+IL-17+ (h) CD4 T cells are shown in HVL and LVL patients. P-values of Mann–Whitney tests are indicated on 
each panel.
FigUre 1 | Patients with higher levels of cD8 T-cell activation show lower ex vivo cD4 T-cell responsiveness in early Phi. Patients were segregated 
based on the level of ex vivo CD8 T-cell activation at baseline: the group with higher immune activation (HIA) was defined as % HLA-DR+CD38+ CD8 
T cells ≥ median and the group with lower immune activation (LIA) as % HLA-DR+CD38+ CD8 T cells < median (a). Plasma viral load (B), CD4 T-cell counts (c), 
% HLA-DR+ CD4 T cells (D), and % Ki-67+ CD4 T cells (e) are depicted in both patient groups. Freshly isolated CD4 T cells (at baseline) were stimulated with PMA/
ionomycin for 5 h and frequencies of IFN-γ+ (F), IL-17+ (g), IFN-γ+IL-17+ (h), as well as of IFN-γ+IL-2+ (i) CD4 T cells are shown in HIA and LIA patients. The ratios 
between effector Th1 responses (% IFN-γ+) and ex vivo CD25+CD127lowFoxP3+ regulatory T cells are also depicted (J). P-values of Mann–Whitney tests are 
indicated on each panel.
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FigUre 3 | levels of hiV-specific il-2+ cD4 T cells strongly correlate with the plasma viral load and the blood hiV reservoir size in early Phi. 
Frequencies of gag-p24-specific IL-2+ CD4 T cells in patients with PHI (at baseline) were correlated to plasma HIV-RNA levels (a), and to total cell-associated 
HIV-DNA levels in the blood (B). Spearman’s rank correlation coefficients (R) and corresponding p-values are indicated on each panel.
FigUre 4 | hiV-specific cD4 T-cell responses follow-up in untreated and arT-treated patient with Phi. Frequencies of HIV-1 gag-p24-specific IFN-γ+ (a) 
and IL-2+ (B) CD4 T cells in patients at baseline (BL) and month 6 of follow-up (M6) in both untreated patients and patients receiving ART after enrollment. Wilcoxon 
rank tests were performed and p-values are indicated between time points. (c) The frequency of HIV-1 gag-p24-specific IFN-γ+ CD4 T cells at month 6 of follow-up 
in treated patients was correlated to the time interval between estimated date of infection and treatment initiation. The Spearman’s rank correlation coefficient (R) 
and corresponding p-value are indicated.
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early treatment initiation may allow patients to better maintain 
these responses.
DiscUssiOn
This study highlights interrelationships between immune activa-
tion, viral replication and T-cell responses in PHI. We showed 
that a high immune activation level in PHI was associated with 
lower polyclonal IFN-γ+ and IL-17+ T-cell responses, while no 
association was found with HIV-specific T-cell frequencies. 
Conversely, we found that a high viral load was associated with 
higher HIV-specific Th1 and Th17 cell responses. Besides, ART-
mediated viral control was associated with a decrease in IFN-γ-
producing HIV-specific CD4 T cells from BL to M6, although the 
earlier ART was introduced, the higher was the residual IFN-γ+ 
HIV-specific CD4 responses. These data highlight that early viral 
replication induces HIV-specific CD4 T cells, but also systemic 
immune activation associated with a down modulation of the 
functional capacities of bulk CD4 T-cells.
Generalized immune activation is known to be a major 
contributor to HIV-1 pathogenesis (20). The potential causes of 
immune activation in chronic HIV infection are well described 
and include a direct effect of the virus or mediated by HIV viral 
proteins, an homeostatic response to CD4 lymphopenia, innate 
and adaptive immune responses, microbial translocation and 
reactivation of other viruses (e.g., CMV) [reviewed in Appay and 
Sauce (21)]. The mechanisms leading to immune activation in 
PHI have been less clearly deciphered. We show here that levels 
of HIV-specific responses are not associated with peripheral CD8 
T-cell activation. We previously demonstrated that microbial 
translocation does not occur at the time of PHI (16). We also 
reported the strong relationship between innate responses and 
CD8 T-cell activation (16). We may rule out a role for CD4 T-cell 
proliferation as a result of CD4 lymphopenia. Indeed, both groups 
HIA and LIA exhibited similar CD4 cell counts and did not sig-
nificantly differ regarding CD4 T-cell proliferation as measured 
by Ki-67 expression. Altogether, our data support the hypothesis 
that, in PHI, systemic T-cell activation is primarily driven by HIV 
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itself and the consequent innate immune activation rather than 
microbial translocation or CD4 T-cell responses.
We found that patients with HIA exhibited higher levels of 
CD4 T-cell activation and lower peripheral polyclonal effector 
Th1 and Th17 CD4 T-cell responses. Low polyclonal effector 
CD4 T-cell responses could result from early functional impair-
ment of bulk memory CD4 T cells. Alternatively, it could be the 
consequence of a sequestration of memory CD4 T lymphocytes 
in lymph nodes and/or gastrointestinal tract, preferential sites of 
viral replication.
While HIV-specific effector CD4 T-cell responses were similar 
between HIA and LIA patients, higher HIV-specific Th1, Th17, 
and Th1/Th17 responses were detected among HVL patients 
compared to LVL patients. This underlines that these cells are 
driven by the viral burden. Accordingly, IFN-γ-specific CD4 T 
cells significantly decreased following introduction of antiretro-
viral treatment. In contrast, specific IL-2+ CD4 cells remained 
unchanged or increased in few patients, although they correlated 
with viral load at BL. This is in line with data reported by Harari 
et  al. in chronic HIV infection indicating that prolonged ART 
diminished IFNγ- but increased IL-2-producing Gag-specific 
CD4 T cells (22). We may speculate that IFN-γ+ cells are part of 
the acute inflammatory response to the virus, while IL-2 is more 
long-term expressed, even after viral suppression, alongside spe-
cific CD4 T-cell proliferation, which is also rescued under ART 
(3). In untreated patients, the frequency of IFN-γ+ and IL-2+ cells 
remained unchanged between BL and month 6 of follow-up for 
most patients, indicating that patients were assessed at a time 
close to the peak of CD4 cell response, in accordance with a 
previous report (11).
While proliferative and IFN-γ+ HIV-specific CD4 responses 
were extensively described, the presence of HIV-specific Th17 
cells has been debated. Indeed, Th17 cells are involved in the 
defense against bacteria and fungi. Virus-specific Th17 cells were 
not detectable in patients with chronic untreated HIV infection 
(23). Yue et al. showed that HIV-specific IL-17-producing CD4 T 
cells were low/undetectable in chronic HIV infection but detect-
able in early infection suggesting that these cells are depleted 
during chronic infection (24). As CMV-specific Th17 cells were 
also found in early HIV infection, but not in the chronic phase 
(where CMV-specific Th1 cells are although still detectable), there 
might be an inflammatory milieu due to high viral replication in 
acute infection, that may aberrantly prime virus-specific T cells to 
produce IL-17 (24). Of note, most IL-17+ CD4 T cells expressed 
CCR6 (Figure S1C in Supplementary Material) and were found 
to decrease with viral suppression under ART. This chemokine 
receptor is regulating Th17 cell migration to the gut-associated 
lymphoid tissue and identifies preferential HIV target cells (25).
The positive relationship that we and others (11) observed 
between the intensity of specific CD4 T-cell responses and 
plasma viral load suggests that CD4 responses do not contribute 
to the control of viral replication in this early phase of infection. 
This does not rule out, however, that early anti-HIV CD4 T cells 
are important for the subsequent establishment of a low viral set 
point (4) and have a beneficial influence on disease outcome, as 
shown in the SPARTAC trial (12). Accordingly, the crucial role 
of CD4 T cells has recently been highlighted by the identification 
of HLA class II alleles associated with high or low viremia (5), 
and by the delineation of immune correlates of protection in 
the RV144 vaccine trial (8). The beneficial outcome of CD4 
T-cell help most likely relies on the ability of cytokine-secreting 
antigen-specific CD4 T-cells (i) to rescue exhausted CD8 T 
cells, as shown in a model of chronic viral infection (26), and 
(ii) to provide B-cell help to mount effective antibody responses, 
as emphasized by HIV vaccine studies (8, 9). In light of that, 
the negative correlation between time to ART initiation after 
infection and the levels of IFN-γ+ HIV-specific CD4 responses 
maintained at month 6 further supports the importance of early 
treatment.
Taken together, these data illustrate the complex interrela-
tionships between virus, immune activation and CD4 T-cell 
responses. Of note, patients with high viral load who exhibited 
higher effector CD4 T-cell responses could even more benefit 
from the early introduction of ART, allowing better maintenance 
of protective HIV-specific CD4 T cell responses.
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FigUre s1 | representative plots of intracellular cytokine staining (ics). 
CD4+ T cells were isolated from PHI patients and stimulated with PMA and 
ionomycin for 5 h (a) or co-cultured with autologous monocytes and with or 
without recombinant HIV gag p24 protein (B). ICS was performed to assess 
expression of the indicated cytokines in CD3+CD4+ cells, and boolean gates 
were used for the analysis. (c) CCR6 expression is shown on IL-17+ cells (open 
histogram) as compared to CD4 T cells (filled histogram) following PMA and 
ionomycin stimulation (left panel) or p24 specific stimulation (right panel). Most 
IL-17+ cells express CCR6 corroborating IL-17 staining specificity.
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